Vera Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

VERA$30.03-1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2024	2023	2024	2023
Operating expenses:
Research and development	$29,311	$16,231	$52,511	$41,340
General and administrative	8,032	5,739	15,944	11,887
Total operating expenses	37,343	21,970	68,455	53,227
Loss from operations	(37,343)	(21,970)	(68,455)	(53,227)
Other income (expense):
Interest income	5,104	2,239	9,290	3,862
Interest expense	(1,912)	(914)	(3,819)	(1,789)
Other income	450	511	904	953
Change in fair value of non-marketable equity securities	(7)	(28)	(11)	(30)
Total other income	3,635	1,808	6,364	2,996
Net loss	$(33,708)	$(20,162)	$(62,091)	$(50,231)
Other comprehensive income (loss):
Change in unrealized (loss) gain on marketable securities	(277)	(138)	(700)	82
Comprehensive loss	$(33,985)	$(20,300)	$(62,791)	$(50,149)
Net loss per share attributable to common stockholders, basic and diluted	$(0.62)	$(0.46)	$(1.17)	$(1.23)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	54,728,552	44,269,772	52,850,242	40,986,907

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.